{"version": "https://jsonfeed.org/version/1.1", "title": "Sharemaestro Newsreel: United States Medical Instruments & Supplies news", "home_page_url": "https://sharemaestro.com/newsreel/us/healthcare/medical-instruments-supplies/", "feed_url": "https://sharemaestro.com/newsreel/us/healthcare/medical-instruments-supplies/feed.json", "description": "Latest Medical Instruments & Supplies company headlines from United States, newest first, with source links and direct routes to company research and sentiment.", "language": "en", "items": [{"id": "source:7a92c6b19227f993f9d52ad3ce521cc34e10bddf97df9b2d301ee4f7b1588245", "url": "https://finance.yahoo.com/healthcare/articles/solv-plans-health-information-systems-153500752.html", "external_url": "https://finance.yahoo.com/healthcare/articles/solv-plans-health-information-systems-153500752.html", "title": "SOLV Plans Health Information Systems Business Spinoff to Drive Growth", "content_text": "Solventum SOLV plans to separate its Health Information Systems (HIS) business as part of its portfolio optimization strategy. The move is expected to sharpen the company's focus on its core MedSurg and Dental Solutions businesses while allowing HIS to pursue its growth opportunities as a standalone entity. From an investor perspective, the planned separation could unlock shareholder value by creating a more focused MedTech business and enabling targeted capital allocation toward Solventum's higher-priority growth areas. HIS, which generates $1.4 billion in annual sales and serves more than 75", "date_published": "2026-08-14T15:35:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "SOLV"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "SOLV", "name": "Solventum Corp.", "sentiment_url": "https://sharemaestro.com/sentiment/0626925f-2978-45fc-9494-16d48c76261f/"}]}}, {"id": "source:52ad4603ac245cae116035e468d0e14a2e773fce3ed16737918ac6e720acbe0f", "url": "https://finance.yahoo.com/healthcare/articles/resmed-rmd-q4-2026-earnings-151328568.html", "external_url": "https://finance.yahoo.com/healthcare/articles/resmed-rmd-q4-2026-earnings-151328568.html", "title": "ResMed (RMD) Q4 2026 Earnings Call Transcript", "content_text": "Image source: The Motley Fool. DATE Thursday, Aug. 6, 2026 at 4:30 p.m. ET CALL PARTICIPANTS Chief Investor Relations Officer-Salli Schwartz Chairman and Chief Executive Officer-Mick Farrell Chief Financial Officer-Aaron Bloomer Full Conference Call Transcript Operator: Hello, and welcome to the Q4 Fiscal Year 2026 ResMed Earnings Conference Call. My name is Kevin, and I'll be your operator for today's call. At this time, all participants are in a listen-only mode. Please note this conference call is being recorded. Later, we'll conduct a question-and-answer session. Let me hand the call over ", "date_published": "2026-08-14T15:13:28+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "RMD"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "RMD", "name": "ResMed Inc", "sentiment_url": "https://sharemaestro.com/sentiment/c28a1de4-d485-455d-b927-eaa8ea7d6ba9/"}]}}, {"id": "source:3867f38903211fe31df8beee1f705b15facf0957d5ce688d44948f6a47fedc61", "url": "https://simplywall.st/stocks/us/healthcare/nyse-bdx/becton-dickinson/news/why-is-becton-dickinson-bdx-getting-fresh-attention-today", "external_url": "https://simplywall.st/stocks/us/healthcare/nyse-bdx/becton-dickinson/news/why-is-becton-dickinson-bdx-getting-fresh-attention-today", "title": "Why Is Becton Dickinson (BDX) Getting Fresh Attention Today?", "content_text": "Becton Dickinson (BDX) is gaining attention after completing enrollment in its PREVENT clinical trial for Phasix Mesh, a significant step towards future U.S. regulatory submission. The stock has seen strong short-term gains, up over 20% in the last 30 days, raising questions about whether this reflects pipeline progress or over-optimistic sentiment. Despite a current undervaluation narrative, risks remain concerning trade headwinds or the potential costs of its Biosciences and Diagnostic Solutions separation.", "date_published": "2026-08-14T06:50:16+00:00", "authors": [{"name": "Simply Wall Street"}], "tags": ["Earnings", "BDX"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "BDX", "name": "Becton Dickinson and Company", "sentiment_url": "https://sharemaestro.com/sentiment/6aba813b-91f7-4ccb-9be9-4b65d6114b01/"}]}}, {"id": "source:755e08322079301b0a62c7e44b92b66969961563142b7071b229bb6dc075162c", "url": "https://www.nasdaq.com/articles/dentsply-sirona-xray-q2-2026-earnings-call-transcript", "external_url": "https://www.nasdaq.com/articles/dentsply-sirona-xray-q2-2026-earnings-call-transcript", "title": "Dentsply Sirona (XRAY) Q2 2026 Earnings Call Transcript", "content_text": "Image source: The Motley Fool. DATE Thursday, Aug. 6, 2026 at 4:30 p.m. ET CALL PARTICIPANTS Investor Relations - Wade MoodyPresident and Chief Executive Officer - Daniel T. ScavillaExecutive Vice President and Chief Financial Officer - John C. Fortson TAKEAWAYS Revenue -- $898 million, representing a 4.1% reported decline or 6.3% on a constant currency basis.Adjusted Revenue -- declined 3.6% on a constant currency basis when excluding the impact of Byte and an $8 million planned dealer inventory reduction.Adjusted EPS -- $0.52, which was flat year over year and included a $0.17 per share posi", "date_published": "2026-08-14T04:45:09+00:00", "authors": [{"name": "nasdaq.com"}], "tags": ["Earnings", "XRAY"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "XRAY", "name": "Dentsply Sirona Inc", "sentiment_url": "https://sharemaestro.com/sentiment/de36aca3-dde4-4d28-a57f-0f98f85d881c/"}]}}, {"id": "source:9425dddcaa6388c09929bd1a7fd1cdf305c4e9f477ce9660fd75d609993ad122", "url": "https://news.google.com/rss/articles/CBMid0FVX3lxTE1rdlBhOFBvMXJoZ2JkOGZPZl9Ec0lzekJYTGw1OGVwdWt2NEUwaHlMWFJVZi0yX1lXNFpDaVRoYy1qaFc2aEpPSm5XTFU1a0F5dUk2cVlzdlpBc01BaW1teUFyRU1fRE9iaTFyNkd0ZkU1MmVKYXFF?oc=5", "external_url": "https://news.google.com/rss/articles/CBMid0FVX3lxTE1rdlBhOFBvMXJoZ2JkOGZPZl9Ec0lzekJYTGw1OGVwdWt2NEUwaHlMWFJVZi0yX1lXNFpDaVRoYy1qaFc2aEpPSm5XTFU1a0F5dUk2cVlzdlpBc01BaW1teUFyRU1fRE9iaTFyNkd0ZkU1MmVKYXFF?oc=5", "title": "ICU Medical (ICUI) Q2 2026 Earnings Call Transcript", "content_text": "ICU Medical (ICUI) Q2 2026 Earnings Call Transcript", "date_published": "2026-08-14T00:31:48+00:00", "authors": [{"name": "AOL.com"}], "tags": ["Earnings", "ICUI"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "ICUI", "name": "ICU Medical Inc", "sentiment_url": "https://sharemaestro.com/sentiment/6fa2c68d-c5c4-4574-b77f-76fa6724e4bc/"}]}}, {"id": "source:72284fbee96e71588edd309afb1bb00e11cb1b2d90fd9f1d29a978c92f0ebed2", "url": "https://news.google.com/rss/articles/CBMiYEFVX3lxTE9EZWo3YVBkVHhTT2VaY3VoT2VnSXBMQ29xTTg2N1hkS25CRUdORG9iMnY2VVdMY3FQenhORlJtVUVQSC10dVBHNzRucjgxa1hQSTNBSDRmWHFndGtCUExqbg?oc=5", "external_url": "https://news.google.com/rss/articles/CBMiYEFVX3lxTE9EZWo3YVBkVHhTT2VaY3VoT2VnSXBMQ29xTTg2N1hkS25CRUdORG9iMnY2VVdMY3FQenhORlJtVUVQSC10dVBHNzRucjgxa1hQSTNBSDRmWHFndGtCUExqbg?oc=5", "title": "MDLN News Today | Why did Medline stock go up today?", "content_text": "MDLN News Today | Why did Medline stock go up today?", "date_published": "2026-08-14T00:10:09+00:00", "authors": [{"name": "MarketBeat"}], "tags": ["Market update", "MDLN"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "MDLN", "name": "Medline Inc. Class A Common Stock", "sentiment_url": "https://sharemaestro.com/sentiment/7339f842-d5b6-494a-b6ee-59cce2c49b92/"}]}}, {"id": "source:53b312960bbed973d29c10bddac22404e68d7577f1ea0e61e1e32a12a2bc1459", "url": "https://www.nasdaq.com/articles/pulse-biosciences-plse-q2-2026-earnings-call-transcript", "external_url": "https://www.nasdaq.com/articles/pulse-biosciences-plse-q2-2026-earnings-call-transcript", "title": "Pulse Biosciences (PLSE) Q2 2026 Earnings Call Transcript", "content_text": "Image source: The Motley Fool. DATE Thursday, Aug. 6, 2026 at 4:30 p.m. ET CALL PARTICIPANTS Investor Relations - Philip TaylorCo-Chair of the Board and Chief Executive Officer - Paul LaVioletteChief Financial Officer - Jon SkinnerCo-Chair of the Board - Bob Duggan Need a quote from a Motley Fool analyst? Email pr@fool.com TAKEAWAYS Total Revenue -- $434,000 for the second quarter, representing disposable sales of the Vybrance system for soft tissue ablation.GAAP Net Loss -- $24.7 million, compared to a net loss of $19.2 million in the prior year period.Cash and Cash Equivalents -- $101.6 mill", "date_published": "2026-08-13T23:31:31+00:00", "authors": [{"name": "nasdaq.com"}], "tags": ["Earnings", "PLSE"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "PLSE", "name": "Pulse Biosciences Inc", "sentiment_url": "https://sharemaestro.com/sentiment/abad14e6-13b8-4a6a-b92c-e516cbbdc9aa/"}]}}, {"id": "source:2267dc8e999a9c50c449f95d50199d342c3e85fc59db80193415c14f3393120c", "url": "https://simplywall.st/stocks/us/healthcare/nasdaq-staa/staar-surgical/news/staar-surgical-staa-stock-price-shrugs-off-profit-rebound-as", "external_url": "https://simplywall.st/stocks/us/healthcare/nasdaq-staa/staar-surgical/news/staar-surgical-staa-stock-price-shrugs-off-profit-rebound-as", "title": "STAAR Surgical (STAA) Stock Price Shrugs Off Profit Rebound As China Dominates", "content_text": "STAAR Surgical reported a strong Q2 2026, returning to profit with $8.1 million in net income and $93.5 million in sales, largely driven by significant growth in China. Despite these positive results, the stock price barely moved, reflecting investor concerns about the company's heavy reliance on the China market and a single product category, as well as unresolved geopolitical and supply chain risks. The article highlights both the bullish case, centered on China's contribution to profitability, and the bearish concerns regarding durability and diversification.", "date_published": "2026-08-13T23:31:04+00:00", "authors": [{"name": "Simply Wall Street"}], "tags": ["Earnings", "STAA"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "STAA", "name": "STAAR Surgical Company", "sentiment_url": "https://sharemaestro.com/sentiment/0aaf3af5-1f47-421a-861d-492b444847cb/"}]}}, {"id": "source:f720a2e60953fbbbc424a27fd60691624de91de7e82111fec63ce6646e0dd36e", "url": "https://kalkine.com.au/news/announcements/resmed-inc-files-annual-form-10-k-report-for-fiscal-year-ended-june-30-2026", "external_url": "https://kalkine.com.au/news/announcements/resmed-inc-files-annual-form-10-k-report-for-fiscal-year-ended-june-30-2026", "title": "ResMed Inc. Files Annual Form 10-K Report for Fiscal Year Ended June 30, 2026", "content_text": "ResMed Inc. has filed its annual Form 10-K report with the U.S. SEC for the fiscal year ended June 30, 2026, detailing key corporate and financial information. The report confirmed that as of August 10, 2026, ResMed had 144,252,306 shares of Common Stock outstanding and a market capitalization of $34,917,180,979 for non-affiliate held equity as of December 31, 2025. The company is classified as a large accelerated filer listed on the NYSE under RMD and has confirmed compliance with internal control over financial reporting requirements.", "date_published": "2026-08-13T23:14:56+00:00", "authors": [{"name": "Kalkine"}], "tags": ["Earnings", "RMD"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "RMD", "name": "ResMed Inc", "sentiment_url": "https://sharemaestro.com/sentiment/c28a1de4-d485-455d-b927-eaa8ea7d6ba9/"}]}}, {"id": "source:d54a806f31005f4078e8a5cc7efd88fcf6f1e638d92186c81ef37a93ff047d7a", "url": "https://news.google.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?oc=5", "external_url": "https://news.google.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?oc=5", "title": "Bausch + Lomb (BLCO) Could Be 57% Undervalued As Board Refresh Draws Attention", "content_text": "Bausch + Lomb (BLCO) Could Be 57% Undervalued As Board Refresh Draws Attention", "date_published": "2026-08-13T23:05:28+00:00", "authors": [{"name": "simplywall.st"}], "tags": ["Market update", "BLCO"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "BLCO", "name": "Bausch + Lomb Corp", "sentiment_url": "https://sharemaestro.com/sentiment/5d34df53-fa6f-440c-aec2-1a6b0cb980f5/"}]}}, {"id": "source:77b6b88f9dfa98351eaeec97554088f931f18810cc1e32a2b54d8b3b9e8be6b4", "url": "https://finance.yahoo.com/healthcare/articles/could-alcon-alc-rxsight-rxst-224910777.html", "external_url": "https://finance.yahoo.com/healthcare/articles/could-alcon-alc-rxsight-rxst-224910777.html", "title": "Could Alcon (ALC) and RxSight (RXST)\u2019s Partnership Reshape the Future of Cataract Surgery?", "content_text": "Two ophthalmic technology leaders, Alcon Inc. (NYSE:ALC) and RxSight, Inc. (NASDAQ:RXST), earlier on July 6 entered into a strategic collaboration that highlights the evolving landscape of cataract and refractive surgery. The companies announced a non-exclusive pact to co-develop post-operatively adjustable pseudophakic intraocular lenses (PCIOLs). By pairing RxSight's proprietary light-adjustable technology, which allows eye surgeons to fine-tune a patient's vision using UV light after surgery, with Alcon's global commercial footprint and surgical equipment portfolio, the agreement validates ", "date_published": "2026-08-13T22:49:10+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "ALC"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "ALC", "name": "Alcon AG", "sentiment_url": "https://sharemaestro.com/sentiment/04015aa2-76d0-47b2-b1a5-76a2a51af34c/"}]}}, {"id": "source:70b5de193326d0c50b27eaaf960121eef4d8b19b22da14a18b0f3bb43bf0a0c5", "url": "https://www.morgancountycitizen.com/news/national/mdln-investigation-kessler-topaz-meltzer-check-llp-encourages-medline-inc-nasdaq-mdln-investors-to-contact/article_26acf338-cb6c-5dd2-8651-37f708887757.html", "external_url": "https://www.morgancountycitizen.com/news/national/mdln-investigation-kessler-topaz-meltzer-check-llp-encourages-medline-inc-nasdaq-mdln-investors-to-contact/article_26acf338-cb6c-5dd2-8651-37f708887757.html", "title": "MDLN Investigation: Kessler Topaz Meltzer & Check, LLP Encourages Medline Inc. (NASDAQ: MDLN) Investors to Contact the Firm", "content_text": "Kessler Topaz Meltzer & Check, LLP is investigating potential violations of federal securities laws by Medline Inc. (NASDAQ: MDLN) on behalf of investors who experienced significant financial losses. This investigation follows a June 2, 2026, FDA warning letter citing \"significant violations\" of manufacturing regulations and subsequent stock price drops in response to the FDA letter and lower financial guidance. Investors who purchased Medline Class A common stock and incurred losses are encouraged to contact the firm to discuss their legal rights.", "date_published": "2026-08-13T22:42:47+00:00", "authors": [{"name": "Morgan County Citizen"}], "tags": ["Regulatory and legal", "MDLN"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "MDLN", "name": "Medline Inc. Class A Common Stock", "sentiment_url": "https://sharemaestro.com/sentiment/7339f842-d5b6-494a-b6ee-59cce2c49b92/"}]}}, {"id": "source:1bfdf0df69acd65abce8b66afe0645ae06ee27183502739e87268410f29be85c", "url": "https://simplywall.st/stocks/us/healthcare/nasdaq-xray/dentsply-sirona/news/is-dentsply-sironas-xray-steady-buyback-and-reaffirmed-outlo/amp", "external_url": "https://simplywall.st/stocks/us/healthcare/nasdaq-xray/dentsply-sirona/news/is-dentsply-sironas-xray-steady-buyback-and-reaffirmed-outlo/amp", "title": "Is DENTSPLY SIRONA\u2019s (XRAY) Steady Buyback and Reaffirmed Outlook Reframing Its Risk\u2011Reward Profile?", "content_text": "DENTSPLY SIRONA (XRAY) reported Q2 2026 sales of US$898 million, returning to a net income of US$37 million, and reaffirmed its full-year 2026 sales guidance of US$3.5 billion to US$3.6 billion, despite lower year-on-year revenue. The company continued its share buyback program, repurchasing 1.3 million shares for US$12.92 million. This mixed performance, coupled with the reaffirmed guidance, necessitates a reassessment of the company's investment narrative, particularly concerning its turnaround strategy and the impact of revenue pressures on profitability.", "date_published": "2026-08-13T22:40:09+00:00", "authors": [{"name": "Simply Wall Street"}], "tags": ["Earnings", "XRAY"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "XRAY", "name": "Dentsply Sirona Inc", "sentiment_url": "https://sharemaestro.com/sentiment/de36aca3-dde4-4d28-a57f-0f98f85d881c/"}]}}, {"id": "source:e6f9273fa8f139e88cc85e1110efb16b0a613bc30dffa2995aa5b6e05f633e82", "url": "https://www.tradingview.com/news/tradingview:620b6194da6dc:0-resmed-inc-fy-2026-revenue-5-65b-eps-10-43-10-k-summary", "external_url": "https://www.tradingview.com/news/tradingview:620b6194da6dc:0-resmed-inc-fy-2026-revenue-5-65b-eps-10-43-10-k-summary", "title": "RESMED INC FY 2026: Revenue $5.65B, EPS $10.43\u2014 10-K Summary", "content_text": "ResMed Inc. reported strong fiscal year 2026 results, with net revenue climbing to $5.65 billion, a 9.9% increase year-over-year, and diluted EPS reaching $10.43. The company saw growth across all regions, driven by device and mask sales, and improved operational efficiencies led to a higher gross margin. Strategic moves included the acquisition of Noctrix and the divestiture of its MatrixCare business.", "date_published": "2026-08-13T21:38:50+00:00", "authors": [{"name": "TradingView"}], "tags": ["Deals and strategy", "RMD"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "RMD", "name": "ResMed Inc", "sentiment_url": "https://sharemaestro.com/sentiment/c28a1de4-d485-455d-b927-eaa8ea7d6ba9/"}]}}, {"id": "source:928823bcde70bb7367b7a01d4b7cf5f0da09d639dff31e4c00c60b5634135b1b", "url": "https://finance.yahoo.com/healthcare/articles/heartflow-htfl-reports-q2-loss-213502995.html", "external_url": "https://finance.yahoo.com/healthcare/articles/heartflow-htfl-reports-q2-loss-213502995.html", "title": "HeartFlow (HTFL) Reports Q2 Loss, Beats Revenue Estimates", "content_text": "HeartFlow (HTFL) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of a loss of $0.14. This compares to a loss of $1.46 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of +50.00%. A quarter ago, it was expected that this medical technology company would post a loss of $0.18 per share when it actually produced a loss of $0.16, delivering a surprise of +11.11%. Over the last four quarters, the company has surpassed consensus EPS estimates three times. HeartFlow, which belongs to th", "date_published": "2026-08-13T21:35:02+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "COO"], "_sharemaestro": {"country": "United States", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "COO", "name": "The Cooper Companies, Inc", "sentiment_url": "https://sharemaestro.com/sentiment/fb8c4c8a-230e-4385-b3c3-23ede12b5bbf/"}]}}, {"id": "source:f3bdbf7d25741a265455e4def2746ec846d07046d1e4b189bfdcaa2b6ff0d45c", "url": "https://m.investing.com/news/analyst-ratings/jefferies-cuts-staar-surgical-stock-price-target-on-estimate-update-93CH-4859270?ampMode=1", "external_url": "https://m.investing.com/news/analyst-ratings/jefferies-cuts-staar-surgical-stock-price-target-on-estimate-update-93CH-4859270?ampMode=1", "title": "Jefferies cuts STAAR Surgical stock price target on estimate update", "content_text": "Jefferies has lowered its price target for STAAR Surgical (NASDAQ:STAA) to $28 from $29, while maintaining a Hold rating, following the company's second-quarter 2026 results. STAAR Surgical reported Q2 revenue of $93.5 million, beating consensus estimates, with strong China sales, but missed earnings per share expectations at $0.16 versus $0.22. Despite the earnings miss, the company showed robust sales growth, particularly in China, and solid financial flexibility.", "date_published": "2026-08-13T21:12:02+00:00", "authors": [{"name": "Investing.com"}], "tags": ["Earnings", "STAA"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "STAA", "name": "STAAR Surgical Company", "sentiment_url": "https://sharemaestro.com/sentiment/0aaf3af5-1f47-421a-861d-492b444847cb/"}]}}, {"id": "source:78a52d321d39f26ea7ede3b9e93dbd0d313f42fc10284238f06fbaacbeabd175", "url": "https://www.stocktitan.net/sec-filings/STVN/schedule-13g-stevanato-group-s-p-a-passive-investment-disclosure-5-6d5bf70842b3.html", "external_url": "https://www.stocktitan.net/sec-filings/STVN/schedule-13g-stevanato-group-s-p-a-passive-investment-disclosure-5-6d5bf70842b3.html", "title": "Artisan Partners (STVN) discloses 2.6M Stevanato shares held for clients", "content_text": "Artisan Partners entities have reported a beneficial ownership of 2,601,598 ordinary shares in Stevanato Group S.p.A. This stake represents 5.2% of the class, based on 49,709,718 shares outstanding as of March 31, 2026. The shares are held on behalf of discretionary clients of Artisan Partners Limited Partnership, who receive dividends and sale proceeds.", "date_published": "2026-08-13T20:40:42+00:00", "authors": [{"name": "Stock Titan"}], "tags": ["Market update", "STVN"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "STVN", "name": "Stevanato Group SpA", "sentiment_url": "https://sharemaestro.com/sentiment/e70ac75e-0f63-4c06-8538-6ba6f9b3b253/"}]}}, {"id": "source:4861984326934dd0a9b429abe027fd0b94553f5bffb7b0b2a7bbe52afea0e2f0", "url": "https://www.theglobeandmail.com/investing/markets/stocks/BAC/pressreleases/3837267/kaplan-fox-is-investigating-medline-inc-nasdaq-mdln-for-potential-securities-law-violations-investors-are-encouraged-to-contact-the-firm", "external_url": "https://www.theglobeandmail.com/investing/markets/stocks/BAC/pressreleases/3837267/kaplan-fox-is-investigating-medline-inc-nasdaq-mdln-for-potential-securities-law-violations-investors-are-encouraged-to-contact-the-firm", "title": "Kaplan Fox is Investigating Medline Inc. (NASDAQ: MDLN) for Potential Securities Law Violations - Investors are Encouraged to Contact the Firm", "content_text": "Kaplan Fox & Kilsheimer LLP is investigating Medline Inc. (NASDAQ: MDLN) for potential securities law violations after the FDA issued a warning letter on June 2, 2026, citing significant violations of manufacturing regulations. This news caused Medline's stock to drop by 7.16%. The investigation encourages investors who suffered losses or have relevant information to contact the firm.", "date_published": "2026-08-13T19:42:48+00:00", "authors": [{"name": "The Globe and Mail"}], "tags": ["Market update", "MDLN"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "MDLN", "name": "Medline Inc. Class A Common Stock", "sentiment_url": "https://sharemaestro.com/sentiment/7339f842-d5b6-494a-b6ee-59cce2c49b92/"}]}}, {"id": "source:3bef01e419d9d389253447d91603c1c8fa9617bbef41a880e7bc6b80a5efa330", "url": "https://finance.yahoo.com/markets/stocks/articles/why-netflix-stock-popped-today-192704519.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/why-netflix-stock-popped-today-192704519.html", "title": "Why Netflix Stock Popped Today", "content_text": "This article first appeared on GuruFocus. Bill Ackman (Trades, Portfolio)'s Pershing Square Capital Management has built a new position in Netflix (NASDAQ:NFLX), returning to the streaming company after a costly exit in 2022, according to a six-month financial report. Warning! GuruFocus has detected 2 Warning Sign with SNDK. Is NFLX fairly valued? Test your thesis with our free DCF calculator. Netflix stock rose 4% after the report on Thursday. The investment totals 3.15 million shares and represents 4.9% of Pershing Square's portfolio. Ackman's latest move marks a reversal from his earlier de", "date_published": "2026-08-13T19:27:04+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "ALC"], "_sharemaestro": {"country": "United States", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "ALC", "name": "Alcon AG", "sentiment_url": "https://sharemaestro.com/sentiment/04015aa2-76d0-47b2-b1a5-76a2a51af34c/"}]}}, {"id": "source:cf0748fc59d9aceed27a4364f0e035fde029d48047637e92d900061e02d755d2", "url": "https://finance.yahoo.com/markets/stocks/articles/bill-ackman-buys-back-netflix-191039109.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/bill-ackman-buys-back-netflix-191039109.html", "title": "Bill Ackman Buys Back Into Netflix Four Years After Selling at a Loss", "content_text": "This article first appeared on GuruFocus. Bill Ackman (Trades, Portfolio) disclosed six new holdings, buying Netflix (NASDAQ:NFLX), Visa (NYSE:V), Mastercard (NYSE:MA), eye care company Alcon (NYSE:ALC), exchange operator Intercontinental Exchange (NYSE:ICE) and financial data provider S&P Global (NYSE:SPGI) from the second quarter onward. The shares sit across his funds, including Pershing Square USA (NYSE:PSUS). Pershing Square USA shares were up 1.66% on the day. Ackman said he thinks the companies' earnings are set for strong growth, which he treats as the main driver of investment value o", "date_published": "2026-08-13T19:10:39+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "ALC"], "_sharemaestro": {"country": "United States", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "ALC", "name": "Alcon AG", "sentiment_url": "https://sharemaestro.com/sentiment/04015aa2-76d0-47b2-b1a5-76a2a51af34c/"}]}}, {"id": "source:6f74f773bca4ce4a50516c1985b3baa72048dc6f408052746cee2e5d123b96e0", "url": "https://www.morningstar.com/news/business-wire/20260813336841/align-climbs-to-no-1572-on-the-2026-inc-5000", "external_url": "https://www.morningstar.com/news/business-wire/20260813336841/align-climbs-to-no-1572-on-the-2026-inc-5000", "title": "Align Climbs to No. 1,572 on the 2026 Inc. 5000", "content_text": "Align, a global provider of technology infrastructure solutions and Managed IT Services, has been named to the 2026 Inc. 5000 list for the third consecutive year, ranking at No. 1,572. This marks a significant advancement from its previous rankings, driven by increased demand for its Data Center Solutions and expanding Managed Services, particularly within the financial services sector. The company attributes its continuous growth to adapting to market changes, understanding client needs, and expanding capabilities in areas like AI and infrastructure modernization.", "date_published": "2026-08-13T18:40:28+00:00", "authors": [{"name": "Morningstar"}], "tags": ["Market update", "ALGN"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "ALGN", "name": "Align Technology Inc", "sentiment_url": "https://sharemaestro.com/sentiment/8ec06d33-caf2-4e93-bd46-560545c31167/"}]}}, {"id": "source:952c873f81ab96624ac63bc332ffb79701fd95b1aa0ecb02687f71eb5756a45b", "url": "https://news.google.com/rss/articles/CBMixgFBVV95cUxPMmcydlJMQzVBQmJaanNvTVVva1BEMnJ6OGtxU0RGQnVYdzlhY3J1bVlTMEc5Y25NZXVNaDgtaEhNaDJYdEN2NjZ1MHQyR2c4Vi1IN1ZJQnRxbGVWWGhqLUVrWWZlRFRzTGFhY1VhbmEwai0zUkZnQmRvSW5CRTJ4RTVzVEpqbXMwUU1zZjV1R0V2NVl1U092SXpJeUtRbHNqX1BEWGppajN5Yll3c1FtSFlMbmNuLWVyUHFYOGoxRVY1WlJiNFE?oc=5", "external_url": "https://news.google.com/rss/articles/CBMixgFBVV95cUxPMmcydlJMQzVBQmJaanNvTVVva1BEMnJ6OGtxU0RGQnVYdzlhY3J1bVlTMEc5Y25NZXVNaDgtaEhNaDJYdEN2NjZ1MHQyR2c4Vi1IN1ZJQnRxbGVWWGhqLUVrWWZlRFRzTGFhY1VhbmEwai0zUkZnQmRvSW5CRTJ4RTVzVEpqbXMwUU1zZjV1R0V2NVl1U092SXpJeUtRbHNqX1BEWGppajN5Yll3c1FtSFlMbmNuLWVyUHFYOGoxRVY1WlJiNFE?oc=5", "title": "Becton, Dickinson: An Earnings Beat Again As Diverse Clinical Portfolio Keeps On Growing", "content_text": "Becton, Dickinson: An Earnings Beat Again As Diverse Clinical Portfolio Keeps On Growing", "date_published": "2026-08-13T18:13:27+00:00", "authors": [{"name": "Seeking Alpha"}], "tags": ["Earnings", "BDX"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "BDX", "name": "Becton Dickinson and Company", "sentiment_url": "https://sharemaestro.com/sentiment/6aba813b-91f7-4ccb-9be9-4b65d6114b01/"}]}}, {"id": "source:a037eecd9aac32645ee2d0d31d4fd7f24611ea1ba15b64b64008f2e6918df676", "url": "https://finance.yahoo.com/markets/stocks/articles/investors-buy-wst-hvp-growth-174800264.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/investors-buy-wst-hvp-growth-174800264.html", "title": "Should Investors Buy WST as HVP Growth Meets a Premium Valuation?", "content_text": "West Pharmaceutical Services, Inc. WST is delivering faster High-Value Product (HVP) growth, wider margins and higher 2026 earnings expectations. Second-quarter organic sales rose 12.7%, while adjusted earnings increased 28.8% to $2.37 per share. The question is whether those gains justify a valuation well above industry levels. WST's growth drivers remain attractive, but the premium multiple leaves less room for operational missteps. WST's HVP Growth Supports the Bull Case HVP Components generated $424.1 million in second-quarter sales, or 49% of total company revenues, and grew 18.4% organic", "date_published": "2026-08-13T17:48:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "WST"], "_sharemaestro": {"country": "United States", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "WST", "name": "West Pharmaceutical Services Inc", "sentiment_url": "https://sharemaestro.com/sentiment/7aadc2b4-93a2-43f5-b352-2bca7b3eeb41/"}]}}, {"id": "source:d2b8070a7f11de2bcc7d266e2f82a94fb7c534645525c7d5d6d1821803b2ad18", "url": "https://finance.yahoo.com/healthcare/articles/wst-q2-beat-raised-2026-174800503.html", "external_url": "https://finance.yahoo.com/healthcare/articles/wst-q2-beat-raised-2026-174800503.html", "title": "WST Q2 Beat and Raised 2026 Outlook Reinforce the HVP Growth Story", "content_text": "West Pharmaceutical Services, Inc. WST turned a better-than-expected second quarter into a higher 2026 outlook. Organic sales growth accelerated, margins widened and adjusted earnings increased sharply, giving investors a clearer read on how High-Value Product demand is translating into financial performance. The quarter matters because the guidance increase was supported by broad HVP momentum rather than a single product line. Execution risks remain in West Vantage and the SmartDose transition, but the earnings trajectory improved. WST's Q2 Beat Resets 2026 Expectations Adjusted earnings rose", "date_published": "2026-08-13T17:48:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "WST"], "_sharemaestro": {"country": "United States", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "WST", "name": "West Pharmaceutical Services Inc", "sentiment_url": "https://sharemaestro.com/sentiment/7aadc2b4-93a2-43f5-b352-2bca7b3eeb41/"}]}}, {"id": "source:c110d8697e9640f9d86702bb9d23a6246f374043536098d1f584b93851fa39b8", "url": "https://www.massdevice.com/alcon-terminates-powervision-iol-program", "external_url": "https://www.massdevice.com/alcon-terminates-powervision-iol-program", "title": "Alcon terminates PowerVision IOL programs, takes $402M write-off", "content_text": "Alcon has terminated its PowerVision intraocular lens (IOL) programs after clinical study data revealed unpredictable postoperative outcomes, leading to a $402 million write-off in the second quarter. CEO David Endicott stated that the programs did not meet their visual performance and patient outcome standards. Despite this setback, Alcon is continuing to invest in next-generation IOL technology, including a new collaboration with RxSight to develop adjustable presbyopia-correcting IOLs.", "date_published": "2026-08-13T17:40:07+00:00", "authors": [{"name": "MassDevice"}], "tags": ["Deals and strategy", "ALC"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "ALC", "name": "Alcon AG", "sentiment_url": "https://sharemaestro.com/sentiment/04015aa2-76d0-47b2-b1a5-76a2a51af34c/"}]}}, {"id": "source:3bae075523d82f329620c017edb16482eb870a556c4812021b23e379975ca88e", "url": "https://www.marketbeat.com/instant-alerts/pulse-biosciences-nasdaqplse-sets-new-1-year-high-time-to-buy-2026-08-13", "external_url": "https://www.marketbeat.com/instant-alerts/pulse-biosciences-nasdaqplse-sets-new-1-year-high-time-to-buy-2026-08-13", "title": "Pulse Biosciences (NASDAQ:PLSE) Sets New 1-Year High - Time to Buy?", "content_text": "Pulse Biosciences (NASDAQ:PLSE) stock reached a new 52-week high of $46.03, closing at $46.75, despite reporting weaker-than-expected quarterly results. Analyst sentiment is mixed, with a \"Moderate Buy\" consensus but an average price target below the current trading price. Institutional investors hold a significant 76.95% of the company's shares.", "date_published": "2026-08-13T17:12:37+00:00", "authors": [{"name": "MarketBeat"}], "tags": ["Earnings", "PLSE"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "PLSE", "name": "Pulse Biosciences Inc", "sentiment_url": "https://sharemaestro.com/sentiment/abad14e6-13b8-4a6a-b92c-e516cbbdc9aa/"}]}}, {"id": "source:81205c8ad0b6668993db3e0320e50ff24e7a6c619fa44ac9e8181dc6eadd6e38", "url": "https://finance.yahoo.com/healthcare/articles/lensar-q2-earnings-call-highlights-170437968.html", "external_url": "https://finance.yahoo.com/healthcare/articles/lensar-q2-earnings-call-highlights-170437968.html", "title": "LENSAR Q2 Earnings Call Highlights", "content_text": "Key Points Interested in LENSAR, Inc.? Here are five stocks we like better. LENSAR's second-quarter revenue rose 18% to $16.5 million, driven by a 20% increase in recurring revenue to $13.7 million and a 23% increase in procedure revenue. GAAP net income reached $3.5 million, while adjusted EBITDA rose to a record $3.6 million. Procedure volume increased 13% year over year to 58,682, and U.S. market share reached 24.1%. LENSAR placed 10 ALLY systems during the quarter, bringing the ALLY installed base to about 215 systems and total global installations to 445. Gross margin improved to about 59", "date_published": "2026-08-13T17:04:37+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "ALC"], "_sharemaestro": {"country": "United States", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "ALC", "name": "Alcon AG", "sentiment_url": "https://sharemaestro.com/sentiment/04015aa2-76d0-47b2-b1a5-76a2a51af34c/"}]}}, {"id": "source:c05e101117320c1e95951383a2e0481aa9e8893bc9f168a3afa8158464cfc1ea", "url": "https://finance.yahoo.com/markets/stocks/articles/lensar-inc-q2-2026-earnings-170038305.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/lensar-inc-q2-2026-earnings-170038305.html", "title": "LENSAR, Inc. Q2 2026 Earnings Call Summary", "content_text": "LENSAR, Inc. Q2 2026 Earnings Call Summary - Moby Strategic Reset and Operational Performance Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here. Management successfully transitioned back to independent operations following the termination of the Alcon merger, focusing on rebuilding commercial momentum and long-term sustainability. Revenue growth of 18% was primarily driven by a 23% increase in procedure revenue, reflecting higher utilization of the ALLY system across the expanding installed ba", "date_published": "2026-08-13T17:00:38+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Deals and strategy", "ALC"], "_sharemaestro": {"country": "United States", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "ALC", "name": "Alcon AG", "sentiment_url": "https://sharemaestro.com/sentiment/04015aa2-76d0-47b2-b1a5-76a2a51af34c/"}]}}, {"id": "source:e9e2fdb689cfb4c605c9d2d35cbfa878c0056805c0cb8911abe8ea11f2cc5885", "url": "https://www.stocktitan.net/sec-filings/ICUI/schedule-13g-a-icu-medical-inc-de-amended-passive-investment-disclosu-529ebd33c99b.html", "external_url": "https://www.stocktitan.net/sec-filings/ICUI/schedule-13g-a-icu-medical-inc-de-amended-passive-investment-disclosu-529ebd33c99b.html", "title": "Janus Henderson holds 11.1% of ICU Medical (ICUI) common stock via clients", "content_text": "Janus Henderson Group Ltd. has reported a beneficial ownership of 2,781,621 shares of ICU Medical, Inc. common stock, which constitutes 11.1% of the class. These shares are held through various Managed Portfolios where Janus Henderson's affiliated Asset Managers exercise investment and voting discretion, though the economic benefits like dividends and sale proceeds accrue to the Managed Portfolios, not Janus Henderson. No single Managed Portfolio owns more than five percent of ICU Medical's common stock.", "date_published": "2026-08-13T16:47:05+00:00", "authors": [{"name": "Stock Titan"}], "tags": ["Market update", "ICUI"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "ICUI", "name": "ICU Medical Inc", "sentiment_url": "https://sharemaestro.com/sentiment/6fa2c68d-c5c4-4574-b77f-76fa6724e4bc/"}]}}, {"id": "source:cd1daadee8cf41bcf61743ca94b82a458f51e0a5a64d25ef06869c120cfdb371", "url": "https://www.theglobeandmail.com/investing/markets/markets-news/motley/3834023/teleflex-tfx-q2-2026-earnings-call-transcript", "external_url": "https://www.theglobeandmail.com/investing/markets/markets-news/motley/3834023/teleflex-tfx-q2-2026-earnings-call-transcript", "title": "Teleflex (TFX) Q2 2026 Earnings Call Transcript", "content_text": "Teleflex reported a 4.7% increase in pro forma adjusted constant currency revenue for Q2 2026, driven by strong Vascular and Surgical segment performance, despite Interventional segment integration challenges. The company completed a $1.5 billion OEM divestiture to fund debt reduction and share repurchases, and it raised its full-year adjusted EPS guidance due to lower interest expenses and share buybacks. Teleflex also highlighted the FDA approval of EZPLAZ and advancements in its Freesolve clinical trials, emphasizing a strategic shift toward core critical care and high-acuity markets.", "date_published": "2026-08-13T16:10:18+00:00", "authors": [{"name": "The Globe and Mail"}], "tags": ["Deals and strategy", "TFX"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "TFX", "name": "Teleflex Incorporated", "sentiment_url": "https://sharemaestro.com/sentiment/6409fb4c-5317-41ed-8401-c307e448779e/"}]}}, {"id": "source:dc33a8e974715ea8b11833e255d59b7bf08522d2e2860c887c85abb4524dc60b", "url": "https://www.stocktitan.net/sec-filings/XRAY/schedule-13g-dentsply-sirona-inc-passive-investment-disclosure-5-8f24488c87e9.html", "external_url": "https://www.stocktitan.net/sec-filings/XRAY/schedule-13g-dentsply-sirona-inc-passive-investment-disclosure-5-8f24488c87e9.html", "title": "DENTSPLY SIRONA (XRAY) gains AQR Capital as 5.22% beneficial owner", "content_text": "AQR Capital Management, LLC and its parent, AQR Capital Management Holdings, LLC, have reported a 5.22% beneficial ownership in DENTSPLY SIRONA Inc. (XRAY), amounting to 10,458,771 shares. This disclosure was made via a Schedule 13G SEC filing, indicating a passive investment with shared voting and dispositive power over all shares. The filing details the entities' beneficial ownership, which is not intended to change or influence the control of the issuer.", "date_published": "2026-08-13T15:40:09+00:00", "authors": [{"name": "Stock Titan"}], "tags": ["Market update", "XRAY"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "XRAY", "name": "Dentsply Sirona Inc", "sentiment_url": "https://sharemaestro.com/sentiment/de36aca3-dde4-4d28-a57f-0f98f85d881c/"}]}}, {"id": "source:3923c7ce8fb834b13e949585c4f8383e9b7283882d4c89f8638cb357ca0e27e3", "url": "https://www.tradingview.com/news/tradingview:1f52155f63325:0-staar-surgical-company-stock-12-month-price-target-cut-to-28-89-implies-14-upside", "external_url": "https://www.tradingview.com/news/tradingview:1f52155f63325:0-staar-surgical-company-stock-12-month-price-target-cut-to-28-89-implies-14-upside", "title": "STAAR Surgical Company Stock 12\u2011Month Price Target Cut to $28.89, Implies 14% Upside", "content_text": "STAAR Surgical Company's average 12-month price target has been reduced to $28.89 from $29.33, according to estimates from 9 analysts. This updated target suggests a potential upside of approximately 14% based on the August 12 closing price. The consensus rating for the stock remains \"Hold\" among 11 analysts, with 2 recommending \"Buy\", 8 \"Hold\", and 1 \"Sell\".", "date_published": "2026-08-13T15:40:04+00:00", "authors": [{"name": "TradingView"}], "tags": ["Analyst action", "STAA"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "STAA", "name": "STAAR Surgical Company", "sentiment_url": "https://sharemaestro.com/sentiment/0aaf3af5-1f47-421a-861d-492b444847cb/"}]}}, {"id": "source:3bec54d3bf7ec8c391f4104861349aadc0e30456575983739eca1728f8680038", "url": "https://finance.yahoo.com/markets/stocks/articles/gehc-lmat-better-value-stock-154003397.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/gehc-lmat-better-value-stock-154003397.html", "title": "GEHC or LMAT: Which Is the Better Value Stock Right Now?", "content_text": "Investors interested in Medical - Products stocks are likely familiar with GE HealthCare Technologies (GEHC) and LeMaitre Vascular (LMAT). But which of these two stocks presents investors with the better value opportunity right now? Let's take a closer look. There are plenty of strategies for discovering value stocks, but we have found that pairing a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system produces the best returns. The Zacks Rank favors stocks with strong earnings estimate revision trends, and our Style Scores highlight companies with specif", "date_published": "2026-08-13T15:40:03+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "LMAT"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "LMAT", "name": "LeMaitre Vascular Inc", "sentiment_url": "https://sharemaestro.com/sentiment/c32596a9-d7e9-4610-ac4c-781999741dc3/"}]}}, {"id": "source:87d98a31c7426da156ca36d4f6e9818147040292bf0c6b0be1121ff3a4f39d07", "url": "https://finance.yahoo.com/markets/stocks/articles/angiodynamics-ango-8-9-since-153002141.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/angiodynamics-ango-8-9-since-153002141.html", "title": "AngioDynamics (ANGO) Up 8.9% Since Last Earnings Report: Can It Continue?", "content_text": "A month has gone by since the last earnings report for AngioDynamics (ANGO). Shares have added about 8.9% in that time frame, outperforming the S&P 500. But investors have to be wondering, will the recent positive trend continue leading up to its next earnings release, or is AngioDynamics due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important drivers. AngioDynamics Q4 Earnings Beat Estimates, Gross Margin Expands AngioDynamics reported an adjusted los", "date_published": "2026-08-13T15:30:02+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "ANGO"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "ANGO", "name": "AngioDynamics Inc", "sentiment_url": "https://sharemaestro.com/sentiment/0562e666-b566-4efb-a281-9d1639b1ee1d/"}]}}, {"id": "source:a57ab9ff6bf4a20b8173e3a2b86a423a6a332c7531d73d20ba9a5faee830400f", "url": "https://www.theglobeandmail.com/investing/markets/stocks/CAH/pressreleases/3832649/revvity-launches-superflex-prenatal-screening-system-for-smaller-labs", "external_url": "https://www.theglobeandmail.com/investing/markets/stocks/CAH/pressreleases/3832649/revvity-launches-superflex-prenatal-screening-system-for-smaller-labs", "title": "Revvity Launches SuperFlex Prenatal Screening System for Smaller Labs", "content_text": "Revvity, Inc. launched the SuperFlex prenatal screening system, a compact, CE-IVDR-certified automated immunoassay instrument designed for small to mid-sized laboratories and clinics. This system aims to expand access to prenatal and preeclampsia testing with its ability to process up to 60 tests per hour and deliver results quickly. The launch is expected to strengthen Revvity's position in the reproductive health market and capitalize on the growing demand for preeclampsia screening.", "date_published": "2026-08-13T15:09:20+00:00", "authors": [{"name": "The Globe and Mail"}], "tags": ["Earnings", "COO"], "_sharemaestro": {"country": "United States", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "COO", "name": "The Cooper Companies, Inc", "sentiment_url": "https://sharemaestro.com/sentiment/fb8c4c8a-230e-4385-b3c3-23ede12b5bbf/"}]}}, {"id": "source:37823f38c65907f316dcb216ce397396f279151ec7bd4b7c7cacb24fdc153929", "url": "https://finance.yahoo.com/markets/stocks/articles/pershing-square-h1-earnings-call-150609179.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/pershing-square-h1-earnings-call-150609179.html", "title": "Pershing Square H1 Earnings Call Highlights", "content_text": "Pershing Square (LON:PSH) held its first earnings call as Pershing Square Inc., with Chief Executive Officer and Chairman Bill Ackman outlining a strategy centered on long-term compounding in its existing investment vehicles, potential new fund launches and efforts to improve trading in Pershing Square USA Ltd. shares. Ackman said the firm's principal focus remains investment performance rather than frequent fundraising. He said Pershing Square expects the earnings of its portfolio companies to compound over time and believes the holdings are currently undervalued. In turn, he said, increases ", "date_published": "2026-08-13T15:06:09+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "ALC"], "_sharemaestro": {"country": "United States", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "ALC", "name": "Alcon AG", "sentiment_url": "https://sharemaestro.com/sentiment/04015aa2-76d0-47b2-b1a5-76a2a51af34c/"}]}}, {"id": "source:12fa92c009cd2a7c0e725526e978fd57a7b9fe1d6785e1b103be65c9df95d5c4", "url": "https://ca.finance.yahoo.com/research/reports/MS_0P0001MVUC_AnalystReport_1786576968000", "external_url": "https://ca.finance.yahoo.com/research/reports/MS_0P0001MVUC_AnalystReport_1786576968000", "title": "Stevanato Group S.p.A. (STVN) Stock Forecasts", "content_text": "Morningstar has initiated coverage on Stevanato Group S.p.A. (STVN) with a narrow moat rating and a fair value estimate of USD 21.10. The shares are currently considered fairly valued at their current price of 21.52. Stevanato Group provides glass and polymer drug containment, drug delivery, and diagnostic solutions to the pharmaceutical and life sciences industries through its Biopharmaceutical and Diagnostic Solutions segment.", "date_published": "2026-08-13T14:40:42+00:00", "authors": [{"name": "Yahoo! Finance Canada"}], "tags": ["Analyst action", "STVN"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "STVN", "name": "Stevanato Group SpA", "sentiment_url": "https://sharemaestro.com/sentiment/e70ac75e-0f63-4c06-8538-6ba6f9b3b253/"}]}}, {"id": "source:10f23b5281f4aa106a4d11ff241dabcc53509f1113fbabdd6bba6831e2d3837e", "url": "https://ca.finance.yahoo.com/research/reports/ARGUS_4625_QuantitativeReport_1786492800000", "external_url": "https://ca.finance.yahoo.com/research/reports/ARGUS_4625_QuantitativeReport_1786492800000", "title": "Repligen Corporation (RGEN) Stock Forecasts", "content_text": "Argus has raised its target price for Repligen Corporation (RGEN) to $173.00. Repligen, a global life sciences company, specializes in developing bioprocessing equipment and supplies for manufacturing biologic drugs. The current stock price for RGEN is $167.49.", "date_published": "2026-08-13T14:40:17+00:00", "authors": [{"name": "Yahoo! Finance Canada"}], "tags": ["Earnings", "RGEN"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "RGEN", "name": "Repligen Corporation", "sentiment_url": "https://sharemaestro.com/sentiment/dda313cb-6adf-45e8-82a2-9d0208c85e84/"}]}}, {"id": "source:b32443e142490459809532aa99652e9875a06e08c7f6226c3272045802026648", "url": "https://m.investing.com/news/analyst-ratings/piper-sandler-reiterates-neutral-on-staar-surgical-stock-at-33-93CH-4858417?ampMode=1", "external_url": "https://m.investing.com/news/analyst-ratings/piper-sandler-reiterates-neutral-on-staar-surgical-stock-at-33-93CH-4858417?ampMode=1", "title": "Piper Sandler reiterates Neutral on STAAR Surgical stock at $33", "content_text": "Piper Sandler reiterated a Neutral rating on STAAR Surgical (NASDAQ:STAA) with a $33.00 price target, following the company's second-quarter results. While STAAR Surgical's China business exceeded expectations, generating $52.3 million in revenue, the company missed revenue expectations in other key regions like the United States. Despite overall revenue growth of 51.3% and a significant 57.8% return over the last six months, concerns remain regarding underlying visibility across different geographies.", "date_published": "2026-08-13T14:40:05+00:00", "authors": [{"name": "Investing.com"}], "tags": ["Earnings", "STAA"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "STAA", "name": "STAAR Surgical Company", "sentiment_url": "https://sharemaestro.com/sentiment/0aaf3af5-1f47-421a-861d-492b444847cb/"}]}}, {"id": "source:c69b94687915217095c1106940bae48d8c0f3d2cfaf4610e8b8a60b94172dc73", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxPdlo5a2VkbkVEWmxKdVFDeDN5RWlicm9mSnhOZjYtUEdiWTg3ZGVTZGhXdWl5bDFUNUZLWTZDalVGWnY4Sm93RGUzSUpMSDEtZERtZFF6M1Bzd244WXFtT2pDa2owREJIeGhwcF9IVVVEd0lVYk1ucTBONVlVVWxOczVrLWJsX3JBQV9DUXJTZjZYMmhNemo4QXpSMzA0TlVnUmo2TnFTUmsyNS1CVUM3OFVpOUdkWmRsbktDb2lTVTQ?oc=5", "external_url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxPdlo5a2VkbkVEWmxKdVFDeDN5RWlicm9mSnhOZjYtUEdiWTg3ZGVTZGhXdWl5bDFUNUZLWTZDalVGWnY4Sm93RGUzSUpMSDEtZERtZFF6M1Bzd244WXFtT2pDa2owREJIeGhwcF9IVVVEd0lVYk1ucTBONVlVVWxOczVrLWJsX3JBQV9DUXJTZjZYMmhNemo4QXpSMzA0TlVnUmo2TnFTUmsyNS1CVUM3OFVpOUdkWmRsbktDb2lTVTQ?oc=5", "title": "STAAR Surgical (NASDAQ:STAA) Shares Gap Down Following Analyst Downgrade", "content_text": "STAAR Surgical (NASDAQ:STAA) Shares Gap Down Following Analyst Downgrade", "date_published": "2026-08-13T14:25:29+00:00", "authors": [{"name": "MarketBeat"}], "tags": ["Analyst action", "STAA"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "STAA", "name": "STAAR Surgical Company", "sentiment_url": "https://sharemaestro.com/sentiment/0aaf3af5-1f47-421a-861d-492b444847cb/"}]}}, {"id": "source:c8399dcb3f9b7b2a5ca7056769575a0bcd9de1a2007d1cee80da58576040116c", "url": "https://ng.investing.com/news/stock-market-news/pulse-biosciences-stock-reaches-alltime-high-at-4603-usd-93CH-2658683", "external_url": "https://ng.investing.com/news/stock-market-news/pulse-biosciences-stock-reaches-alltime-high-at-4603-usd-93CH-2658683", "title": "Pulse Biosciences stock reaches all-time high at 46.03 USD By Investing.com", "content_text": "Pulse Biosciences Inc. (PLSE) stock hit an all-time high of $46.03, currently trading near its 52-week high of $45.90, despite a recent report of wider-than-expected Q2 2026 losses and lower revenue. The stock has seen a significant 163.78% one-year increase and 216% year-to-date, boosting its market capitalization to $3.24 billion, though InvestingPro indicates it is overvalued. Positive investor sentiment is driven by progress in its atrial fibrillation trial and other programs, leading Canaccord to raise its price target to $43.", "date_published": "2026-08-13T14:12:37+00:00", "authors": [{"name": "Investing.com Nigeria"}], "tags": ["Earnings", "PLSE"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "PLSE", "name": "Pulse Biosciences Inc", "sentiment_url": "https://sharemaestro.com/sentiment/abad14e6-13b8-4a6a-b92c-e516cbbdc9aa/"}]}}, {"id": "source:d697c741d2ce4d03442834bf02346736cece9151b73fbce35ba70cc7322cf1ee", "url": "https://news.google.com/rss/articles/CBMi1gFBVV95cUxNUDh1dFlTVmxMZXpVV19kdXZwNkNaaHdsZGpPUUNmQ0RTUlBGcXVHdjRUUFpBR19mU0dRZFFVRFQtOWVBRXJJR0pwQTRTRUl2eHV5VXNsdTdHNUNuWG9fTUYxVW9XeTlQVXFlV3JWclU0YkJGbVYzMGk2U0hsbWJEVDlLN3FPSEtkNFFxaDBEdEFrNjkyU2JNRVhWY2IzM3JsTS1ERWZyMGRYZkVRWXlwR2s4cUNLb1NDbXpDVVhaaEFFdU05OUFnMTlkNGZDWUhpck1oNjRB?oc=5", "external_url": "https://news.google.com/rss/articles/CBMi1gFBVV95cUxNUDh1dFlTVmxMZXpVV19kdXZwNkNaaHdsZGpPUUNmQ0RTUlBGcXVHdjRUUFpBR19mU0dRZFFVRFQtOWVBRXJJR0pwQTRTRUl2eHV5VXNsdTdHNUNuWG9fTUYxVW9XeTlQVXFlV3JWclU0YkJGbVYzMGk2U0hsbWJEVDlLN3FPSEtkNFFxaDBEdEFrNjkyU2JNRVhWY2IzM3JsTS1ERWZyMGRYZkVRWXlwR2s4cUNLb1NDbXpDVVhaaEFFdU05OUFnMTlkNGZDWUhpck1oNjRB?oc=5", "title": "Earnings call transcript: SOLV Energy lifts 2026 outlook as revenue jumps in Q2 2026", "content_text": "Earnings call transcript: SOLV Energy lifts 2026 outlook as revenue jumps in Q2 2026", "date_published": "2026-08-13T14:10:18+00:00", "authors": [{"name": "Investing.com"}], "tags": ["Earnings", "SOLV"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "SOLV", "name": "Solventum Corp.", "sentiment_url": "https://sharemaestro.com/sentiment/0626925f-2978-45fc-9494-16d48c76261f/"}]}}, {"id": "source:6cfde676c6fb8deb9a3f613563f32b0a6c7b9e74d2f3a19ab3f9382d2fa3269a", "url": "https://simplywall.st/stocks/us/healthcare/nyse-solv/solventum/news/should-solventums-solv-activist-driven-asset-sales-and-his-s", "external_url": "https://simplywall.st/stocks/us/healthcare/nyse-solv/solventum/news/should-solventums-solv-activist-driven-asset-sales-and-his-s", "title": "Should Solventum\u2019s (SOLV) Activist-Driven Asset Sales and HIS Separation Shift Its Capital Allocation Playbook?", "content_text": "Solventum (SOLV) recently announced slightly higher Q2 2026 results and confirmed that activist investor Trian Fund Management influenced its US$4.10 billion asset sale and plans to separate its Health Information Systems business. Management reiterated a focus on disciplined \"tuck-in\" acquisitions and a growing deal pipeline, suggesting that proceeds from portfolio reshaping will be reinvested into smaller, technology-focused deals aligning with its core MedSurg and Dental franchises. The article explores how this HIS separation could redefine Solventum\u2019s investment narrative and future portfolio strategy, amidst potential operational challenges from its separation from 3M.", "date_published": "2026-08-13T13:46:24+00:00", "authors": [{"name": "Simply Wall Street"}], "tags": ["Deals and strategy", "SOLV"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "SOLV", "name": "Solventum Corp.", "sentiment_url": "https://sharemaestro.com/sentiment/0626925f-2978-45fc-9494-16d48c76261f/"}]}}, {"id": "source:339d387b509a1be53af68828fd16d6f946da310dd87e62bb92b25579d8c9a209", "url": "https://www.marketbeat.com/instant-alerts/staar-surgical-nasdaqstaa-price-target-lowered-to-3700-at-wedbush-2026-08-13", "external_url": "https://www.marketbeat.com/instant-alerts/staar-surgical-nasdaqstaa-price-target-lowered-to-3700-at-wedbush-2026-08-13", "title": "STAAR Surgical (NASDAQ:STAA) Price Target Lowered to $37.00 at Wedbush", "content_text": "Wedbush has lowered its price target for STAAR Surgical (NASDAQ:STAA) to $37.00 from $40.00 but maintained an \"outperform\" rating, indicating a potential upside of 45.61%. Despite this, analyst sentiment is mixed, with an average \"hold\" rating and a consensus price target of $26.61. The company recently exceeded quarterly revenue and EPS estimates, reporting $93.52 million in revenue and $0.10 EPS, with revenue growing 119.6% year over year.", "date_published": "2026-08-13T13:40:05+00:00", "authors": [{"name": "MarketBeat"}], "tags": ["Analyst action", "STAA"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "STAA", "name": "STAAR Surgical Company", "sentiment_url": "https://sharemaestro.com/sentiment/0aaf3af5-1f47-421a-861d-492b444847cb/"}]}}, {"id": "source:94864b78b6281fa043ef47f6a4ab238ba5776c49580b8f36e8fbbb63ea9c121d", "url": "https://finance.yahoo.com/markets/stocks/articles/intuitive-surgical-isrg-backs-long-133733648.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/intuitive-surgical-isrg-backs-long-133733648.html", "title": "Intuitive Surgical (ISRG) Backs Long-Term Moat Amid Near-Term Volatility", "content_text": "TCW Funds, an investment management firm, published its second-quarter 2026 investor letter for the 'TCW Concentrated Large Cap Growth Fund.' A copy of the letter can be downloaded here. During the second quarter, AI monetization, a fragile Middle East ceasefire, and a Federal Reserve leadership transition were the significant events. All major indices ended higher, driven by resilient economic growth and strong corporate earnings. April marked a recovery from March lows, with the S&P 500 achieving record highs by early June, largely due to robust corporate earnings linked to AI capital spendi", "date_published": "2026-08-13T13:37:33+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Capital return", "ISRG"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "ISRG", "name": "Intuitive Surgical Inc", "sentiment_url": "https://sharemaestro.com/sentiment/0a03d394-9146-42ea-b024-6cd13e63f4e4/"}]}}, {"id": "source:e8ebe1a48aef80732bff900da1a117a0bbd971fff1e4c38075a07432e95f3e5a", "url": "https://simplywall.st/stocks/us/healthcare/nyse-rmd/resmed/news/how-investors-may-respond-to-resmed-rmd-dividend-hike-and-ve", "external_url": "https://simplywall.st/stocks/us/healthcare/nyse-rmd/resmed/news/how-investors-may-respond-to-resmed-rmd-dividend-hike-and-ve", "title": "How Investors May Respond To ResMed (RMD) Dividend Hike And Ventilator Recall Headwinds", "content_text": "ResMed (RMD) recently reported strong Q4 and full-year results, increasing its quarterly dividend to US$0.66 per share and completing a US$1.40 billion share buyback. However, the company also faces a softer outlook due to an FDA Class 1 recall of ventilators, suspending sales. This creates a mixed investment narrative where the strength of its sleep-health and digital platforms must offset ventilator-related pressures.", "date_published": "2026-08-13T13:33:23+00:00", "authors": [{"name": "Simply Wall Street"}], "tags": ["Capital return", "RMD"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "RMD", "name": "ResMed Inc", "sentiment_url": "https://sharemaestro.com/sentiment/c28a1de4-d485-455d-b927-eaa8ea7d6ba9/"}]}}, {"id": "source:befccb60e6fa3f650ea020b40c2450558288dfb4825113e87d04104091ec865f", "url": "https://www.marketscreener.com/news/femasys-strengthens-and-extends-global-patent-protection-for-fembloc-with-first-issued-blended-polym-ce7859d9de81f624", "external_url": "https://www.marketscreener.com/news/femasys-strengthens-and-extends-global-patent-protection-for-fembloc-with-first-issued-blended-polym-ce7859d9de81f624", "title": "Femasys Strengthens and Extends Global Patent Protection for FemBloc with First Issued Blended Polymer Patents", "content_text": "Femasys Inc. announced the issuance of new patents in the U.S. and internationally for the blended polymer component of its FemBloc non-surgical permanent birth control technology. These patents expand and strengthen the global intellectual property protection for FemBloc, complementing existing patents for its delivery system. FemBloc is approved in Europe and other international markets, and is currently undergoing a pivotal trial in the U.S.", "date_published": "2026-08-13T13:12:38+00:00", "authors": [{"name": "www.marketscreener.com"}], "tags": ["Market update", "FEMY"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "FEMY", "name": "Femasys Inc", "sentiment_url": "https://sharemaestro.com/sentiment/21a4da2f-a2ec-4359-ac6e-52003a6fc1f9/"}]}}, {"id": "source:9f6428fb3570463636e7b1dfd394baa2d11a55a5faa46678486e9ea53097a682", "url": "https://www.globenewswire.com/news-release/2026/08/13/3344605/0/en/embc-investors-have-opportunity-to-lead-embecta-corp-securities-fraud-lawsuit-with-sbs-law.html", "external_url": "https://www.globenewswire.com/news-release/2026/08/13/3344605/0/en/embc-investors-have-opportunity-to-lead-embecta-corp-securities-fraud-lawsuit-with-sbs-law.html", "title": "EMBC Investors Have Opportunity to Lead Embecta Corp. Securities Fraud Lawsuit with SBS Law", "content_text": "Schall, Brown & Schwartz LLP (SBS) has reminded investors of a class action lawsuit against Embecta Corp. (EMBC) for alleged violations of securities laws. The lawsuit claims Embecta made false and misleading statements regarding its fiscal guidance for Q2 and full-year 2026, failing to disclose challenges in the pen needle market. Investors who purchased EMBC shares during the class period (November 25, 2025 to May 4, 2026) are encouraged to contact SBS by the August 17, 2026 deadline to discuss lead plaintiff opportunities.", "date_published": "2026-08-13T13:12:20+00:00", "authors": [{"name": "GlobeNewswire"}], "tags": ["Regulatory and legal", "EMBC"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "EMBC", "name": "Embecta Corp", "sentiment_url": "https://sharemaestro.com/sentiment/99a8dfac-d8b2-469b-bd12-86bac4537f4b/"}]}}, {"id": "source:1cfcc5a67f27d208043d9a6136656a9709a9bb8e43d1719e55f32e5087a860e3", "url": "https://www.gurufocus.com/news/9031553/icu-medical-inc-icui-chief-information-officer-ben-sousa-sells-2250-shares", "external_url": "https://www.gurufocus.com/news/9031553/icu-medical-inc-icui-chief-information-officer-ben-sousa-sells-2250-shares", "title": "ICU Medical Inc (ICUI) Chief Information Officer Ben Sousa Sells 2,250 Shares", "content_text": "ICU Medical Inc's Chief Information Officer, Ben Sousa, sold 2,250 shares of the company's stock for approximately $401,220. This transaction contributes to a trend of insider selling at the company, with 9 sells versus 2 buys over the last year. The stock is currently deemed \"Significantly Overvalued\" by GuruFocus, trading at $178.32 against an intrinsic value of $120.56.", "date_published": "2026-08-13T13:11:05+00:00", "authors": [{"name": "GuruFocus"}], "tags": ["Earnings", "ICUI"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "ICUI", "name": "ICU Medical Inc", "sentiment_url": "https://sharemaestro.com/sentiment/6fa2c68d-c5c4-4574-b77f-76fa6724e4bc/"}]}}, {"id": "source:9f712be6711e5019f00ddd085e588be57b2c864c46ba1231ff9006e8d61b6087", "url": "https://pluang.com/en/news-feed/lematre-vascular-pemotongan-panduan-31-persen", "external_url": "https://pluang.com/en/news-feed/lematre-vascular-pemotongan-panduan-31-persen", "title": "LeMaitre Vascular remains a Buy despite 31% pullback; strong organic growth and record margins support outlook.", "content_text": "LeMaitre Vascular's stock experienced a 31% drop after missing Q2 2026 expectations due to currency issues, export blockages, and tissue shortages. However, the company demonstrates strong underlying demand with 10% organic sales growth and record-high margins, driven by its fastest-growing product, Artegraft. Despite the valuation reset, its 11% organic growth guidance, solid balance sheet, and expanding biologics portfolio make it a compelling buy, with a price target adjusted to $95-$100 for year-end 2027.", "date_published": "2026-08-13T13:10:08+00:00", "authors": [{"name": "Pluang"}], "tags": ["Earnings", "LMAT"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "LMAT", "name": "LeMaitre Vascular Inc", "sentiment_url": "https://sharemaestro.com/sentiment/c32596a9-d7e9-4610-ac4c-781999741dc3/"}]}}]}